To shareholders and investors
Towa being a pharmaceutical company that specializes in generics and has been dedicated to research and development, production, and marketing of generics for many years. Generics have increasingly played a very important role in the aging society because they are economically affordable for patients and they help curtail the financial burden of the government.
In addition to promoting stable supply, quality assurance, and information provision about generics, Towa focuses on growth with three original strategies.
The first strategy is the development of value-added formulations. As represented by “RACTAB technology,” Towa is focusing on research and development of value-added formulations that can be taken by patients easily and easily handled by medical professionals.
The second strategy is fair price sales. Towa strives to maintain product value by making the most of the Towa brand such as through value-added formulations. We believe that we can continue the product life cycle and secure mid to long-term profits through these efforts.
The third strategy is the Towa sales system. We can meet the needs of medical institutions by establishing two systems: the direct sales system with sales offices and agents throughout Japan and through wholesalers. Towa has established a system to respond to the promotion to use generics from the government.
Towa is characterized by these unique strategies and is clearly different from other companies in the industry. We would appreciate it if you could recognize Towa as a unique company instead of one “commodity” generic Japanese manufacturers.
In IR, Towa strives to achieve timely and appropriate disclosure on the website and also share information about the management status of Towa Pharmaceutical in a timely manner through various means, such as financial analyst meetings, individual investor meetings, and IR Mails., In consequence, shareholders and investors are able to assess the company’s business status accurately.